Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:36:11 2024-04-22 am EDT After market 12:09:56 pm
88.17 EUR +1.47% Intraday chart for Sanofi 88.18 +0.01%
Sales 2024 * 46.28B 49.26B Sales 2025 * 49.73B 52.94B Capitalization 108B 115B
Net income 2024 * 7.46B 7.94B Net income 2025 * 8.68B 9.23B EV / Sales 2024 * 2.49 x
Net Debt 2024 * 6.89B 7.33B Net Debt 2025 * 2.7B 2.87B EV / Sales 2025 * 2.24 x
P/E ratio 2024 *
14.5 x
P/E ratio 2025 *
12.5 x
Employees 86,088
Yield 2024 *
4.39%
Yield 2025 *
4.76%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.47%
1 week+0.82%
Current month-3.07%
1 month-0.54%
3 months-6.40%
6 months-10.31%
Current year-1.77%
More quotes
1 week
85.07
Extreme 85.07
88.59
1 month
85.07
Extreme 85.07
92.04
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
105.18
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-04-22 88.17 +1.47% 1 454 519
24-04-19 86.89 +1.95% 1,871,390
24-04-18 85.23 -1.10% 1,813,622
24-04-17 86.18 -0.70% 1,205,893
24-04-16 86.79 -0.75% 1,201,342

Real-time Euronext Paris, April 22, 2024 at 11:36 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
86.89 EUR
Average target price
107.5 EUR
Spread / Average Target
+23.71%
Consensus